New drug combination for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Pancreatic cancer (ductal adenocarcinoma type) confirmed by biopsy, never treated before, and too advanced to remove surgically or has spread to other organs
- Good overall health and able to care for yourself with minimal help (ECOG score 0–1)
- Expected to live at least 3 months
- Healthy blood counts, liver, and kidney function (based on recent blood work)
- Able to receive radiation therapy without major concerns
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (NALIRIFOX plus immunotherapy) followed by radiation, compared to NALIRIFOX alone, as a way to shrink pancreatic tumors that haven't spread and make them removable. It's for people who haven't had any previous cancer treatment.
This trial tests a combination of two targeted drugs (serplulimab and bevacizumab) plus two different chemotherapy regimens for people with advanced pancreatic cancer that has worsened after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer.
This trial tests a new drug combination given before surgery for pancreatic cancer that has not spread. It includes targeted therapy, chemotherapy, and possibly immunotherapy to see if it can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a new drug combination for people whose pancreatic cancer has grown after their first treatment. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.